Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with breast cancer that can be removed by surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt-Ingram Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Clinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma

• Diagnosis may be made by fine needle aspiration cytology or core biopsy

• A repeat core biopsy is not required for patients who have a paraffin embedded diagnostic core biopsy specimen available for immunohistochemical staining

Exclusion Criteria:

• Patients with locally advanced disease who are planning to undergo preoperative neoadjuvant therapy are not eligible*

• Locally advanced disease includes any of the following:

• Primary tumor ≥ 5 cm (T3)

• Tumor of any size with direct extension to the chest wall or skin (T4a-c)

• Inflammatory breast cancer (T4d)

• Fixed axillary lymph node metastases (N2)

• Metastasis to ipsilateral internal mammary node (N3) NOTE: *Patients with primary tumors ≥ 5 cm (T3) or tumors involving the chest wall or skin who are not candidates for preoperative chemotherapy or who decline preoperative chemotherapy are eligible

• Measurable residual tumor at the primary site

• Measurable disease is defined as any mass that can be reproducibly measured by physical examination

• Planning to undergo surgical treatment with either segmental resection or total mastectomy

• Patients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer

• No locally recurrent breast cancer

• No evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases)

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• ANC ≥ 1,000/mm^3

• Creatinine ≤ 1.5 times upper limit of normal (ULN)

• Total bilirubin ≤ 1.5 times ULN

• Serum glutamic oxaloacetic transminase (SGOT) and serum glutamic pyruvic transminase (SGPT) ≤ 1.5 times ULN

• Must be at least 18 years old

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No serious medical illness that, in the judgement of the treating physician, places the patient at high risk of operative mortality

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior chemotherapy for this primary breast cancer

• At least 7 days since prior tamoxifen or raloxifene as a preventive agent